Clinical trial NCT06620068: Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
Official title: Causal Association Between Plasma Vascular Endothelial Growth Factor Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Placenta Previa
Keywords: Vascular Endothelial Growth Factor (VEGF)
Mendelian Randomization
Angiogenesis
Pregnancy Complications
Placental Development
Lead sponsor: Guangzhou Institute of Respiratory Disease
Sponsor class: OTHER
Collaborators: name: The Second People's Hospital of Foshan
name: First People's Hospital of Foshan
name: Maternal and Child Health Hospital of Foshan
First posted: 2024-10-01
Enrollment: 207473
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study analyzes data from European populations included in genome-wide association studies (GWAS) from UK Biobank and FinnGen, focusing on individuals with available plasma VEGF family protein levels and placenta previa data.

Brief summary: This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach. Genome-wide association study (GWAS) data will be analyzed to assess the correlation and potential causality between VEGF protein levels and the occurrence of placenta previa.

Detailed description: Placenta previa is a serious complication during pregnancy, leading to significant risks for both the mother and the fetus. This study utilizes Mendelian randomization (MR) to explore the potential causal link between plasma levels of VEGF family proteins (including VEGFA, VEGFB, VEGFC, VEGFD, and PLGF) and the risk of placenta previa. By using genome-wide association study (GWAS) data from the UK Biobank and FinnGen datasets, the study aims to provide insights into the role of angiogenesis and abnormal placental development. The MR analysis will help minimize confounding factors and provide robust evidence regarding the causal relationship between VEGF proteins and placenta previa.

Eligibility criteria: Inclusion Criteria:

* Participants included in genome-wide association studies (GWAS) with available data on plasma VEGF family proteins and placenta previa.

Exclusion Criteria:

* Participants with incomplete or missing data on plasma VEGF levels or placenta previa.

Primary outcomes:
measure: Causal relationship between plasma VEGFA levels and the risk of placenta previa
timeFrame: Data analysis and outcome assessment will be completed by December 2024
Secondary outcomes:
measure: Causal relationship between plasma VEGFB levels and the risk of placenta previa
timeFrame: Data analysis and outcome assessment will be completed by December 2024
measure: Causal relationship between plasma VEGFC levels and the risk of placenta previa
timeFrame: Data analysis and outcome assessment will be completed by December 2024
measure: Causal relationship between plasma PLGF levels and the risk of placenta previa
timeFrame: Data analysis and outcome assessment will be completed by December 2024
Other outcomes:
Locations:
Study officials:
References: